Equities

Nuvalent Inc

NUVL:NSQ

Nuvalent Inc

Actions
  • Price (USD)95.42
  • Today's Change1.33 / 1.41%
  • Shares traded265.25k
  • 1 Year change+65.14%
  • Beta1.3107
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. It develops small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases and drive more durable responses. It is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, NVL-520, is being developed for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, NVL-655, is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC. LC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor.

  • Revenue in USD (TTM)0.00
  • Net income in USD-173.59m
  • Incorporated2017
  • Employees115.00
  • Location
    Nuvalent IncOne Broadway, 14th FloorCAMBRIDGE 02142United StatesUSA
  • Phone+1 (857) 357-7000
  • Fax+1 (302) 655-5049
  • Websitehttps://www.nuvalent.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Immunovant Inc0.00-323.01m4.49bn207.00--10.00-----2.21-2.210.003.060.00----0.00-79.97---92.17--------------0.00-------22.93------
Denali Therapeutics Inc0.00-427.49m4.51bn390.00--3.42-----2.76-2.760.009.170.00----0.00-31.77-14.98-33.76-17.71-------104.50----0.0043--204.7420.6755.45--30.70--
Ultragenyx Pharmaceutical Inc522.75m-558.99m4.65bn1.28k--13.40--8.90-6.46-6.466.023.760.37661.916.06409,674.80-40.27-33.35-50.12-38.3086.2593.13-106.93-154.712.65--0.00--19.5253.1814.25--62.91--
Alkermes Plc1.51bn502.58m4.67bn2.10k9.783.618.603.102.951.968.837.990.67881.324.24716,724.3022.671.3428.901.7483.1783.3233.392.123.03--0.18270.0049.618.741,665.99---7.10--
Biohaven Ltd0.00-746.61m5.26bn239.00--12.87-----9.15-9.150.004.160.00----0.00-137.07---176.64--------------0.00------28.43------
Crinetics Pharmaceuticals Inc1.39m-258.54m5.42bn290.00--5.79--3,914.07-3.77-3.770.020110.470.0023--0.41574,775.86-41.16-42.53-44.29-45.36-----18,257.91-5,446.39----0.00---15.2810.57-30.88--34.65--
Arcellx Inc155.82m-40.42m5.54bn130.00--11.52--35.55-0.7196-0.71962.988.950.226----1,198,600.00-5.86-38.82-7.56-45.41-----25.94-339.38----0.022------62.53--113.86--
Krystal Biotech Inc241.52m52.37m5.74bn229.00112.956.4896.6323.771.771.778.2130.800.27251.514.531,054,664.005.91-11.506.33-12.0192.55--21.68-492.857.76--0.00------107.81--39.49--
Ionis Pharmaceuticals Inc803.07m-358.81m6.19bn927.00--9.34--7.71-2.45-2.455.504.200.2670.386410.02866,306.40-11.93-6.30-13.52-7.4498.7098.75-44.68-21.238.82--0.6587--34.105.60-35.80--11.83--
Nuvalent Inc0.00-173.59m6.23bn115.00--9.69-----2.78-2.780.009.840.00----0.00-31.08---32.81--------------0.00-------54.20------
Blueprint Medicines Corp434.41m-128.05m6.41bn638.00--20.43--14.74-2.11-2.116.924.930.37690.89548.11663,227.50-11.11-29.92-13.84-34.0697.01---29.48-116.653.27-10.800.5525--22.2241.149.06--4.85--
Cytokinetics, Inc.3.22m-576.40m6.82bn423.00------2,119.26-5.39-5.390.0301-0.1180.003--2.357,609.93-52.96-43.14-57.95-47.22-----17,906.24-540.47---14.271.02---92.04-24.89-35.30--9.76--
Legend Biotech Corp (ADR)455.99m-285.01m7.38bn2.20k--6.33--16.18-1.57-1.572.516.330.244610.6332.42253,328.30-15.29-37.71-17.63-47.1960.28---62.50-286.514.78--0.2263--143.7042.15-16.11--1.57--
Viking Therapeutics Inc0.00-99.15m7.63bn33.00--8.37-----0.937-0.9370.008.180.00----0.00-15.02-21.91-15.47-23.04------------0.00-------24.73------
Madrigal Pharmaceuticals Inc76.81m-518.67m7.65bn376.00--9.84--99.58-25.07-25.073.7135.640.1172----204,289.90-79.11-62.09-100.35-74.8196.37---675.24--5.93--0.1309-------26.50--132.01--
Data as of Nov 08 2024. Currency figures normalised to Nuvalent Inc's reporting currency: US Dollar USD

Institutional shareholders

44.13%Per cent of shares held by top holders
HolderShares% Held
Fidelity Management & Research Co. LLCas of 30 Jun 20248.86m13.76%
Paradigm BioCapital Advisors LPas of 30 Jun 20244.57m7.10%
The Vanguard Group, Inc.as of 30 Jun 20243.68m5.72%
Perceptive Advisors LLCas of 30 Jun 20242.55m3.96%
BlackRock Fund Advisorsas of 30 Jun 20242.34m3.63%
Fairmount Funds Management LLCas of 30 Jun 20241.92m2.99%
Commodore Capital LPas of 30 Jun 20241.49m2.31%
SSgA Funds Management, Inc.as of 30 Jun 20241.33m2.06%
Woodline Partners LPas of 30 Jun 2024886.08k1.38%
Geode Capital Management LLCas of 30 Jun 2024782.18k1.22%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.